Company intelligence / Profile preview

IDP Pharma

Ownership: Private
Employees: ~7
Development stage: Phase 1

Overview

IDP-121, their first-in-class drug, has been approved to start clinical trials in hematological cancers. It has demonstrated efficacy in animal models and is now being tested in humans for the first time to evaluate side effects, determine appropriate dosage, and observe initial efficacy results.[3][5]

Therapeutic areas: Oncology
Modalities: Small moleculesNew Chemical Entities (NCEs)
Industry: Biotech

Drug pipeline

1 asset

IDP-121

Beyond the preview

Go deeper on IDP Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDP Pharma.

Explore the full profile